What is Zacks Research's Estimate for Exelixis Q1 Earnings?

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of Exelixis in a research note issued on Tuesday, July 1st. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings of $0.55 per share for the quarter, up from their prior estimate of $0.54. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q2 2026 earnings at $0.61 EPS, FY2026 earnings at $2.54 EPS and Q1 2027 earnings at $0.67 EPS.

EXEL has been the topic of a number of other reports. JMP Securities upped their target price on Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating in a research note on Monday, June 23rd. Royal Bank Of Canada reissued an "outperform" rating and set a $40.00 price objective on shares of Exelixis in a report on Wednesday, May 14th. Bank of America upped their price objective on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday, June 5th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, HC Wainwright boosted their price target on shares of Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $43.56.

Exelixis Stock Up 3.6%

Shares of EXEL stock traded up $1.61 on Thursday, reaching $45.91. The company's stock had a trading volume of 6,040,447 shares, compared to its average volume of 2,496,550. The company has a market capitalization of $12.52 billion, a P/E ratio of 20.87, a PEG ratio of 0.93 and a beta of 0.28. Exelixis has a 12-month low of $21.86 and a 12-month high of $49.62. The stock's 50 day simple moving average is $41.88 and its 200-day simple moving average is $37.71.

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 34,387 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $44.06, for a total value of $1,515,091.22. Following the transaction, the executive vice president owned 412,072 shares in the company, valued at approximately $18,155,892.32. The trade was a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Amy C. Peterson sold 72,776 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the transaction, the chief marketing officer directly owned 465,393 shares of the company's stock, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 458,113 shares of company stock valued at $21,024,817. Corporate insiders own 2.85% of the company's stock.

Institutional Trading of Exelixis

Large investors have recently modified their holdings of the business. Coppell Advisory Solutions LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $25,000. Hemington Wealth Management raised its holdings in shares of Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 522 shares in the last quarter. Colonial Trust Co SC lifted its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the period. Bartlett & CO. Wealth Management LLC purchased a new stake in Exelixis in the first quarter worth $37,000. Finally, Costello Asset Management INC bought a new stake in Exelixis in the first quarter valued at $39,000. 85.27% of the stock is owned by institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.